The existence of a small population of ‘cancer-initiating cells’ responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bruce, W. R. & van der Gaag, H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199, 79–80 (1963)
Huntly, B. J. & Gilliland, D. G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nature Rev. Cancer 5, 311–321 (2005)
Scadden, D. T. Cancer stem cells refined. Nature Immunol. 5, 701–703 (2004)
Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001)
Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738–743 (2004)
Holtz, M., Forman, S. J. & Bhatia, R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 67, 1113–1120 (2007)
Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494–501 (2005)
Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290–293 (1973)
de Klein, A. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765–767 (1982)
Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343–3356 (2000)
Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001)
Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645–652 (2002)
Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58–60 (2007)
Ghanima, W., Kahrs, J., Dahl, T. G. & Tjonnfjord, G. E. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur. J. Haematol. 72, 441–443 (2004)
Cortes, J., O’Brien, S. & Kantarjian, H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104, 2204–2205 (2004)
Mauro, M. J., Druker, B. J. & Maziarz, R. T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk. Res. 28, 71–73 (2004)
Merante, S. et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90, 979–981 (2005)
Higashi, T. et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am. J. Hematol. 76, 275–278 (2004)
Bernardi, R. & Pandolfi, P. P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Rev. Mol. Cell Biol. 8, 1006–1016 (2007)
Salomoni, P. & Pandolfi, P. P. The role of PML in tumor suppression. Cell 108, 165–170 (2002)
Wang, Z. G. et al. PML is essential for multiple apoptotic pathways. Nature Genet. 20, 266–272 (1998)
Bernardi, R. et al. PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR. Nature 442, 779–785 (2006)
Gurrieri, C. et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl Cancer Inst. 96, 269–279 (2004)
Scaglioni, P. P. et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126, 269–283 (2006)
Arai, F. et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149–161 (2004)
Pardal, R., Clarke, M. F. & Morrison, S. J. Applying the principles of stem-cell biology to cancer. Nature Rev. Cancer 3, 895–902 (2003)
Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824–830 (1990)
Klaassen, C. D. Heavy metals and heavy-metal antagonists. In The Pharmacological Basis of Therapeutics (eds Hardman, J. G., Gilman, A. G. & Limbird, L. E.) 1649–1672 (McGraw-Hill, New York, 1996)
Aronson, S. M. Arsenic and old myths. R. I. Med. 77, 233–234 (1994)
Mathews, V. et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107, 2627–2632 (2006)
Soignet, S. L. et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339, 1341–1348 (1998)
Shen, Z. X. et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354–3360 (1997)
Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor α degradation. J. Exp. Med. 193, 1361–1371 (2001)
Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475–482 (2006)
Zhang, J. et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518–522 (2006)
Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701–4707 (2003)
Jørgensen, H. G. et al. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Exp. Hematol. 33, 1140–1146 (2005)
Lallemand-Breitenbach, V. et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189, 1043–1052 (1999)
Rego, E. M., He, L. Z., Warrell, R. P., Wang, Z. G. & Pandolfi, P. P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc. Natl Acad. Sci. USA 97, 10173–10178 (2000)
Rego, E. M. et al. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 193, 521–529 (2001)
Gurrieri, C. et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 103, 2358–2362 (2004)
Wang, Z. G. et al. Role of PML in cell growth and the retinoic acid pathway. Science 279, 1547–1551 (1998)
Di Cristofano, A. et al. p62dok, a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210bcr-abl. J. Exp. Med. 194, 275–284 (2001)
Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nature Med. 12, 446–451 (2006)
Cross, N. C. et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br. J. Haematol. 84, 67–74 (1993)
We thank S. Ogilvie for analysis of patient samples and data management, and all members of the Pandolfi laboratory for comments and discussion. K.I. was supported by a JSPS postdoctoral fellowship for research abroad. R.B. is supported by a K01 NIH grant. This work was supported by NIH grants to P.P.P.
Author Contributions The experiments were conceived and designed by K.I., R.B., A.M. and P.P.P. Experiments were performed by K.I., R.B. and A.M. Immunohistochemistry of patient samples was conducted and investigated by J.T.-F, K.I. and R.B. Experiments on primary human CML samples were performed by A.M., S.M., G.S., Y.I., J.R., K.I. and D.E.A. Data were analysed by K.I., R.B., A.M. and P.P.P. The paper was written by K.I., R.B., A.M. and P.P.P.
About this article
Cite this article
Ito, K., Bernardi, R., Morotti, A. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072–1078 (2008). https://doi.org/10.1038/nature07016
Clinical and Translational Oncology (2022)
CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence
International Journal of Hematology (2022)
International Journal of Hematology (2021)
Experimental & Molecular Medicine (2020)
Nature Reviews Cancer (2020)